BACKGROUND: Noninfectious comorbid diseases (NCDs) contribute to morbidity and mortality in human immunodeficiency virus (HIV)-infected populations in resource-rich countries. With antiretroviral therapy (ART) scale-up in Africa, understanding burden NCD informs public health strategy. METHODS: At enrollment, participants at 11 HIV clinics in Kenya, Uganda, Tanzania, and Nigeria underwent medical history, physical, laboratory, and neuropsychological assessments to identify elevated blood pressure, hypercholesterolemia, dysglycemia, renal insufficiency, and cognitive impairment. Poisson regression models estimated adjusted relative risks (ARRs) and 95% confidence intervals (CIs) for the number of NCDs associated with factors of interest. Logistic regression was used to evaluate each NCD separately among HIV-infected participants. RESULTS: Among 2720 participants with complete NCD data, 2159 (79.4%) were HIV-infected. Of those, 1426 (66.0%) were taking ART and 813 (37.7%) had at least 1 NCD. HIV infection was associated with more NCDs, especially with ART (ARR, 1.42; 95% CI, 1.22-1.66). In addition to age, body mass index, and program site, ART usage was associated with more NCDs (ARR, 1.50; 95% CI, 1.27-1.78 for virologically suppressed and ARR, 1.38; 95% CI, 1.13-1.68 for viremic) among HIV-infected participants. In participants taking ART, CD4 nadir below 200 cells/mm3 was associated with more NCDs (ARR, 1.43; 95% CI, 1.06-1.93). ART use was independently associated with hypercholesterolemia and dysglycemia. Program site was significantly associated with all comorbidities except renal insufficiency. CONCLUSIONS: HIV infection was a risk for NCDs, which were common in HIV-infected participants, geographically variable, and largely consistent with metabolic complications of first-line ART. Published by Oxford University Press for the Infectious Diseases Society of America 2018.
BACKGROUND: Noninfectious comorbid diseases (NCDs) contribute to morbidity and mortality in human immunodeficiency virus (HIV)-infected populations in resource-rich countries. With antiretroviral therapy (ART) scale-up in Africa, understanding burden NCD informs public health strategy. METHODS: At enrollment, participants at 11 HIV clinics in Kenya, Uganda, Tanzania, and Nigeria underwent medical history, physical, laboratory, and neuropsychological assessments to identify elevated blood pressure, hypercholesterolemia, dysglycemia, renal insufficiency, and cognitive impairment. Poisson regression models estimated adjusted relative risks (ARRs) and 95% confidence intervals (CIs) for the number of NCDs associated with factors of interest. Logistic regression was used to evaluate each NCD separately among HIV-infectedparticipants. RESULTS: Among 2720 participants with complete NCD data, 2159 (79.4%) were HIV-infected. Of those, 1426 (66.0%) were taking ART and 813 (37.7%) had at least 1 NCD. HIV infection was associated with more NCDs, especially with ART (ARR, 1.42; 95% CI, 1.22-1.66). In addition to age, body mass index, and program site, ART usage was associated with more NCDs (ARR, 1.50; 95% CI, 1.27-1.78 for virologically suppressed and ARR, 1.38; 95% CI, 1.13-1.68 for viremic) among HIV-infectedparticipants. In participants taking ART, CD4 nadir below 200 cells/mm3 was associated with more NCDs (ARR, 1.43; 95% CI, 1.06-1.93). ART use was independently associated with hypercholesterolemia and dysglycemia. Program site was significantly associated with all comorbidities except renal insufficiency. CONCLUSIONS:HIV infection was a risk for NCDs, which were common in HIV-infectedparticipants, geographically variable, and largely consistent with metabolic complications of first-line ART. Published by Oxford University Press for the Infectious Diseases Society of America 2018.
Authors: Franziska Schoeni-Affolter; Bruno Ledergerber; Martin Rickenbach; Christoph Rudin; Huldrych F Günthard; Amalio Telenti; Hansjakob Furrer; Sabine Yerly; Patrick Francioli Journal: Int J Epidemiol Date: 2009-11-30 Impact factor: 7.196
Authors: Victor Valcour; Priscilla Yee; Andrew E Williams; Bruce Shiramizu; Michael Watters; Ola Selnes; Robert Paul; Cecilia Shikuma; Ned Sacktor Journal: J Neurovirol Date: 2006-10 Impact factor: 2.643
Authors: Ned C Sacktor; Matthew Wong; Noeline Nakasujja; Richard L Skolasky; Ola A Selnes; Seggane Musisi; Kevin Robertson; Justin C McArthur; Allan Ronald; Elly Katabira Journal: AIDS Date: 2005-09-02 Impact factor: 4.177
Authors: Susan L Rosenkranz; Kevin E Yarasheski; Michael F Para; Richard C Reichman; Gene D Morse Journal: Metab Syndr Relat Disord Date: 2007-06 Impact factor: 1.894
Authors: Kathy Petoumenos; Signe W Worm; Eric Fontas; Rainer Weber; Stephane De Wit; Mathias Bruyand; Peter Reiss; Wafaa El-Sadr; Antonella D'Arminio Monforte; Nina Friis-Møller; Jens D Lundgren; Matthew G Law Journal: J Int AIDS Soc Date: 2012-10-10 Impact factor: 5.396
Authors: Emmanuel Maganga; Luke R Smart; Samuel Kalluvya; Johannes B Kataraihya; Ahmed M Saleh; Lama Obeid; Jennifer A Downs; Daniel W Fitzgerald; Robert N Peck Journal: PLoS One Date: 2015-08-19 Impact factor: 3.240
Authors: Casey L Smiley; Peter F Rebeiro; Carina Cesar; Pablo F Belaunzaran-Zamudio; Brenda Crabtree-Ramirez; Denis Padgett; Eduardo Gotuzzo; Claudia P Cortes; Jean Pape; Valdiléa G Veloso; Catherine C McGowan; Jessica L Castilho Journal: Lancet HIV Date: 2021-04-20 Impact factor: 12.767
Authors: Tessa Concepcion; Jennifer Velloza; Christopher G Kemp; Amritha Bhat; Ian M Bennett; Deepa Rao; Christina S Polyak; Julie A Ake; Allahna Esber; Nicole Dear; Jonah Maswai; John Owuoth; Valentine Sing'oei; Emmanuel Bahemana; Michael Iroezindu; Hannah Kibuuka; Pamela Y Collins Journal: AIDS Behav Date: 2022-10-09
Authors: Katherine Davis; Pablo Perez-Guzman; Annika Hoyer; Ralph Brinks; Edward Gregg; Keri N Althoff; Amy C Justice; Peter Reiss; Simon Gregson; Mikaela Smit Journal: BMC Med Date: 2021-05-13 Impact factor: 8.775
Authors: Francis Kiweewa; Allahna Esber; Ezra Musingye; Domonique Reed; Trevor A Crowell; Fatim Cham; Michael Semwogerere; Rosemary Namagembe; Alice Nambuya; Cate Kafeero; Allan Tindikahwa; Leigh Anne Eller; Monica Millard; Huub C Gelderblom; Babajide Keshinro; Yakubu Adamu; Jonah Maswai; John Owuoth; Valentine Chepkorir Sing'oei; Lucas Maganga; Emmanuel Bahemana; Samoel Khamadi; Merlin L Robb; Julie A Ake; Christina S Polyak; Hannah Kibuuka Journal: PLoS One Date: 2019-02-05 Impact factor: 3.240
Authors: Emmanuel Bahemana; Allahna Esber; Nicole Dear; Kavitha Ganesan; Ajay Parikh; Domonique Reed; Lucas Maganga; Samoel Khamadi; Mucho Mizinduko; Anange Lwilla; Dorothy Mkondoo; Gwamaka Mwaisanga; Nancy Somi; John Owouth; Jonah Maswai; Francis Kiweewa; Michael Iroezindu; Julie A Ake; Trevor A Crowell; Victor G Valcour; Christina S Polyak Journal: AIDS Res Ther Date: 2020-11-12 Impact factor: 2.250
Authors: Domonique M Reed; Allahna L Esber; Trevor A Crowell; Kavitha Ganesan; Hannah Kibuuka; Jonah Maswai; John Owuoth; Emmanuel Bahemana; Michael Iroezindu; Julie A Ake; Christina S Polyak Journal: AIDS Res Ther Date: 2021-07-22 Impact factor: 2.250
Authors: Allahna L Esber; Peter Coakley; Julie A Ake; Emmanuel Bahemana; Yakubu Adamu; Francis Kiweewa; Jonah Maswai; John Owuoth; Merlin L Robb; Christina S Polyak; Trevor A Crowell Journal: J Int AIDS Soc Date: 2020-02 Impact factor: 5.396
Authors: Elizabeth H Lee; Kavitha Ganesan; Samoel A Khamadi; Stanley C Meribe; Dorothy Njeru; Yakubu Adamu; Fred Magala; Trevor A Crowell; Eniko Akom; Patricia Agaba; Priyanka Desai; Tiffany Hamm; Deydre Teyhen; Julie A Ake; Christina S Polyak; Douglas Shaffer; Fredrick Sawe; Patrick W Hickey Journal: Am J Trop Med Hyg Date: 2021-01 Impact factor: 3.707